Clinical Trial Update: The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating roflumilast as an adjunct to antidepressants in adults with major depressive disorder has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: Sadat City University | Conditions: Major Depressive Disorder | Phase 1, Phase 2 | Status: WITHDRAWN